Recombinant anti-VLA4 antibody molecules

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S130100, C424S133100, C424S134100, C424S136100, C424S141100, C424S143100, C424S153100, C424S154100, C424S173100, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700, C530S388750, C536S023100, C536S023500, C536S023530, C435S252300, C435S320100, C435S326000, C435S343000, C435S343100

Reexamination Certificate

active

07829092

ABSTRACT:
The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4816587 (1989-03-01), Cabilly et al.
patent: 5217870 (1993-06-01), Hession et al.
patent: 5272263 (1993-12-01), Hession et al.
patent: 5367056 (1994-11-01), Hession et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5695755 (1997-12-01), Papayannopoulo
patent: 5824304 (1998-10-01), Papayannopoulo
patent: 5859205 (1999-01-01), Adair et al.
patent: 5871734 (1999-02-01), Lobb et al.
patent: 5888507 (1999-03-01), Burkly
patent: 5932214 (1999-08-01), Lobb et al.
patent: 6252043 (2001-06-01), Hession et al.
patent: 6307025 (2001-10-01), Hession et al.
patent: 6482409 (2002-11-01), Lobb et al.
patent: 6602503 (2003-08-01), Lobb et al.
patent: 7157086 (2007-01-01), Lobb et al.
patent: 7482003 (2009-01-01), Lobb et al.
patent: 0120694 (1984-10-01), None
patent: 0125023 (1984-11-01), None
patent: 0239400 (1987-09-01), None
patent: 0330506 (1989-08-01), None
patent: 0519596 (1992-12-01), None
patent: 86/01533 (1986-03-01), None
patent: 86/05807 (1986-09-01), None
patent: 87/04462 (1987-07-01), None
patent: 89/01036 (1989-02-01), None
patent: 89/07454 (1989-08-01), None
patent: 89/10404 (1989-11-01), None
patent: 90/07861 (1990-07-01), None
patent: 9013300 (1990-11-01), None
patent: 91/09967 (1991-07-01), None
patent: 92/04381 (1992-03-01), None
patent: 9519790 (1995-07-01), None
Harlan, “Leukocyte-Endothelial Interactions” Blood (1985) 65:513-526.
Marcantonio, et al., “Antibodies to the Conserved Cytoplasmic Domain of the Integrin β1 Subunit React with Proteins in Vertebrates, Invertebrates and Fungi” J. Cell. Biol. (1988) 106:1765-1772.
Pober, et al., “Overlapping Patterns of Activation of Human Endothelial Cells by Interleukin 1, Tumor of Necrosis Factor, and Immune Interferon” J. Immunol. (1986) 137:1893-1896.
Albelda et al., “Adhesion molecules and inflammatory injury”, FASEB J. (1994) 8:504-512.
Bebbington et al., “High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker”, Bio/Technology (1992) 10: 169-175.
Bednarczyk et al., “A Monoclonal Antibody to VLAα Chain (CDw49d) Induces Hornotypic Lymphcyte Aggregation”, J. Immunol. (1990) 144:777-784.
Begent et al., “Phase I/II Study of Chimeric B72.3 Antibody in Radioimmunology of Colorectal Carcinoma” Br. J. Cancer (1990) 62:487.
Bevilacqua et al., “Endothelial Leukocyte Adhesion Moldecule 1: An Inducible Receptor for Neutrophils Related to Complement Regulatory Proteins and Lectins”, Science (1989) 243:1160-1165.
Bevilacqua et al., “Identifcation of an Inducible Endothelial-Leukocyte Adhesion Molecule” Proc. Natl. Acad. Sci USA (1987) 84:9238-9242.
Bochner et al., “Adhesion of Human Basophiols, Eosinophils, and Neutrophiles to Interleukin 1-activated Human Vascular Endothelial Cells: Contributions of Endothelial Cell Adhesion Molecules” J. Exp. Med (1991) 173:1553-1556.
Borrebaeck et al., “The Use of in Vitro Immunization, Cloning of Variable Regions, and SCID Mice for the Production of Human Monoclonal Antibodies”, Therapeutic Monoclonal Antibodies (1990) 1: 1-15.
Boyd et al., “Intercellular Adhesion Molecule 1 (ICAM-1) has a Central Role in Cell-Cell Contact-Mediated Immune Mechanisms” Proce. Natl. Acad. Sci USA (1988) 85:3095-3099.
Bruggemann et al. “The Immunogenicity of Chimeric Antibodies” J. Exp Med. (1989) 170:2153-2157.
Bulinkski, “Peptide Antibodies: New Tools for Cell Biology” International Review of Cytology (1986) 103:281-302.
Burkly et al., Eur J. Immunol. (1991) 21:2871-2875.
Carlos et al., “Vascular Cell Adhesion Molecule-1 Mediates Lymphocyte Adherence to Cytokine-Activated Cultured Human Endothelial Cells” Blood (1990) 76:965-970.
Clayberger et al., “Identification and Characterization of Two Novel Lymphocyte Function-Associated Antigens, L24 and L25” J. Immunol. (1987) 138:1510-1514.
Co et al., “Humanized Antibodies for Antiviral Therapy” Proc. Natl. Acad. Sci USA (1991) 88:2869-2873.
Collins et al., “Recombinant Human Tumor Necrosis Factor Increases mRNA Levels and Surface Expression of HLA-A, B Antigens in Vascular Endothelial Cells and Dermal Fibroblasts in Vitro” Proc. Natl. Acad. Sci USA 83:446-450, (1986).
Cybulsky et al., “Endothelial Expression of Mononuclear Leukocyte Adhesion Molecule During Atherogenesis” Science (1991) 251:788-791.
Dobrina et al., “Mechanisms of Eosinophil Adherence to Cultured Vascular Endothelial Cells” J. Clin. Invest. (1991) 88:20-26.
Dustin et al., “Lymphocyte Function-Associated Antigen-1 (LFA01) Interaction with Intercellular Adhesion Molecule-1 (ICAM-1) is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells” J. Cell Biol. (1988) 107:321-331.
Dustin et al., “Induction by IL1 and Interferon-γ: Tissue Distribution, Biochemistry, and Function of a Natural Adherence Molecule (CAM-1)” J. Immunol. (1986) 137:245-254.
Edgington “How Sweet It Is: Selectin-Mediating Drugs” Bio/Technology (1992) 10:383:384.
Elices et al., “VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA4 at a Site Distinct from the VLA4/Fibronectin Binding Site” Cell (1990) 60:577-584.
Favoloro et al., “Transcriptional Maps of Polyoma Virus Specific RNA: Analysis by Two-Dimensional Nuclease S1 Gel Mapping” Methods in Enzymology (1980) 65:718-749.
Flanagan et al., “Arrangelemt of Human Immunoglobulin Heavy Chain COnstruct Region Genes Implies Evolutional Amplification of a Segment Containing γ, ε and α Genes” Nature (1982) 300:709-713.
Freedman et al., “Adhesion of Human B Cells to Germinal Centers in Vitro Involves VLA-4 and INCAM-110” Science (1990) 249:1030-1033.
Hale et al., “Remission Induction in Non-Hodgkin Lymphoma with Reshpaed Human Monoclonal Antibody CAMPATH-1H” Lancet (Dec. 17, 1988) 1394-1398.
Harian, “Leukocyte-Endothelial Interactions” Blood (1985) 65:513-526.
Harris et al., “Therapeutic antibodies—the coming of age” TIBTECH (1993) 11: 42-44.
Hemler, “VLA Proteins in the Integrin Family: Structures, Functions and Their Role on Leukocytes” Anny. Rev. Immunol. (1990) 8:365-400.
Hemler et al., “Characterization of the Cell Surface Heterodimer VLA4 and Related Peptides” J. Biol. Chem. (1991) 262:11476-11485.
Hession et al., “Cloning of an Alternative Form of Vascular Cell Adhesion Molecule-1 (VCAM1” J. Biol. Chem. (1980) 266:6682-6685.
Hieter et al., “Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments” Cell (1991) 22:197-207.
Ho et al., “Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction” Gene (1989) 77:51-59.
Holzmann et al., “Identification of a Murine Peyer's Patch-Specific Lymphocyte Homing Receptor as an Integrin Molecule with an α Chain Homologous to Human VLA-4α” Cell (1989) 56:37-46.
Huse et al., “Generation of a Large Combinatorial Library of Immunoglobulin Repertoire in Phage Lambda” Science (1989) 246:1275-1281.
Hynes, “Integrins: A Family of Cell Surface Receptors” Cell (1987) 48:549-554.
Issekutz, “Inhibition of in Vivo Lymphocyte Migration to Inflammation and H

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Recombinant anti-VLA4 antibody molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-VLA4 antibody molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-VLA4 antibody molecules will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4190742

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.